Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) received the drug registration certificate for its memantine hydrochloride oral solution from China's National Medical Products Administration, a Wednesday filing with the Hong Kong bourse said.
The drug is used to treat moderate to severe Alzheimer's dementia, according to the pharmaceutical firm.